Form 4: ResMed CFO Brett Sandercock Sells 1,000 Shares Under 10b5-1 Plan
SEC Form 4 Filing
ResMed's Chief Financial Officer, Brett Sandercock, sold 1,000 shares of ResMed common stock at a price of $230.36 per share on March 10, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- On March 10, 2025, Brett Sandercock, the Chief Financial Officer of ResMed Inc., sold 1,000 shares of ResMed common stock.
- The sale was executed at a price of $230.36 per share.
- This transaction was conducted under a Rule 10b5-1 plan adopted on February 6, 2024.
- Following the transaction, Sandercock directly owns 90,864 shares of ResMed common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to an insider stock sale under a pre-arranged plan, indicating a neutral sentiment.
Industry Context
Insider transactions are routinely monitored and reported to the SEC. Sales under 10b5-1 plans are common and allow insiders to sell shares over a period of time while avoiding accusations of trading on non-public information.
Stakeholder Impact
- The sale of shares by a high-ranking officer could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 02/06/2024 | Date of adoption of the Rule 10b5-1 plan |
| 03/10/2025 | Date of stock sale transaction |
| 03/11/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.